# M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Source: https://onco.cc/trials/nct06509906/  
OnCo record `nct06509906` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is terminated.

## Summary

The registry lists NCT06509906 as terminated, last updated 2025-12-18. Enrolment is 3 actual participants. Interventions: M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF). Primary measures include Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs; Number of Participants with Dose Limiting Toxicity (DLT). The registry reason for stopping is: Sponsor Decision No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT06509906
- Phase: 1
- Setting: An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT06509906: https://clinicaltrials.gov/study/NCT06509906

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct06509906.json